ArchiMed sells Diesse to Fremman Capital, delivering 4.6x return to shareholders

ArchiMed exited its investment in Diesse through a sale to private equity firm Fremman Capital, generating a 4.6x return for shareholders.

The transaction concludes a five-year partnership in which ArchiMed helped transform Diesse into a leading clinical diagnostics innovator.

Acquired in 2019, Diesse benefited from ArchiMed’s strategic growth initiatives. This included appointing industry veteran Massimiliano Boggetti as CEO and leveraging an expert advisory board. Under ArchiMed’s ownership, Diesse expanded its production capacity. In particular, it launched Europe’s most advanced In Vitro Diagnostics facility in 2023. The company introduced three new analyzer platforms, developed 170 tests, and expects to roll out more than 60 additional tests over the next 12–18 months.

Diesse’s international footprint grew substantially, with sales in over 100 countries and international revenues contributing 70% of its 2024 earnings. The company also expanded its presence with new subsidiaries in the US, Germany, and Brazil.

The sale follows strong interest from strategic and financial buyers. ArchiMed’s MED II fund, which backed Diesse, has now exited six of its 11 investments, delivering a 2.0x return on invested capital. Ranked among the top-performing buyout funds for its 2018 vintage, MED II’s track record underscores ArchiMed’s strength in healthcare-focused private equity.

This successful exit reinforces ArchiMed’s reputation for driving growth and innovation in healthcare businesses. Most notably, it positions Diesse for continued success under Fremman Capital’s ownership.

Source: Archimed

Can’t stop reading? Read more